73 related articles for article (PubMed ID: 18239622)
1. Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells.
Griessinger E; Frelin C; Cuburu N; Imbert V; Dageville C; Hummelsberger M; Sirvent N; Dreano M; Peyron JF
Leukemia; 2008 Jul; 22(7):1466-9. PubMed ID: 18239622
[No Abstract] [Full Text] [Related]
2. AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells.
Griessinger E; Imbert V; Lagadec P; Gonthier N; Dubreuil P; Romanelli A; Dreano M; Peyron JF
Leukemia; 2007 May; 21(5):877-85. PubMed ID: 17330097
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of FLT3 and NF-κB selective inhibitors on acute myeloid leukemia in vivo.
Wang C; Lu J; Wang Y; Bai S; Wang Y; Wang L; Sheng G
J Biochem Mol Toxicol; 2012 Jan; 26(1):35-43. PubMed ID: 21928377
[TBL] [Abstract][Full Text] [Related]
4. Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors.
Muranyi AL; Dedhar S; Hogge DE
Leuk Res; 2010 Oct; 34(10):1358-65. PubMed ID: 20193963
[TBL] [Abstract][Full Text] [Related]
5. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
[TBL] [Abstract][Full Text] [Related]
6. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
7. Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.
Mony U; Jawad M; Seedhouse C; Russell N; Pallis M
Leukemia; 2008 Jul; 22(7):1395-401. PubMed ID: 18509353
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia.
Davies RJ; Pierce AC; Forster C; Grey R; Xu J; Arnost M; Choquette D; Galullo V; Tian SK; Henkel G; Chen G; Heidary DK; Ma J; Stuver-Moody C; Namchuk M
J Med Chem; 2011 Oct; 54(20):7184-92. PubMed ID: 21970471
[TBL] [Abstract][Full Text] [Related]
9. FLT3/ ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signalling.
Katsumi A; Kiyoi H; Abe A; Tanizaki R; Iwasaki T; Kobayashi M; Matsushita T; Kaibuchi K; Senga T; Kojima T; Kohno T; Hamaguchi M; Naoe T
Eur J Haematol; 2011 Mar; 86(3):191-8. PubMed ID: 21114537
[TBL] [Abstract][Full Text] [Related]
10. FLT3 inhibitors in acute myeloid leukemia.
el-Shami K; Stone RM; Smith BD
Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
[TBL] [Abstract][Full Text] [Related]
11. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6.
Takahashi S; Harigae H; Ishii KK; Inomata M; Fujiwara T; Yokoyama H; Ishizawa K; Kameoka J; Licht JD; Sasaki T; Kaku M
Leuk Res; 2005 Aug; 29(8):893-9. PubMed ID: 15978940
[TBL] [Abstract][Full Text] [Related]
13. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.
Heidary DK; Huang G; Boucher D; Ma J; Forster C; Grey R; Xu J; Arnost M; Choquette D; Chen G; Zhou JH; Yao YM; Ball ED; Namchuk M; Davies RJ; Henkel G
J Med Chem; 2012 Jan; 55(2):725-34. PubMed ID: 22221201
[TBL] [Abstract][Full Text] [Related]
14. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
15. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
16. The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.
Kasper S; Breitenbuecher F; Hoehn Y; Heidel F; Lipka DB; Markova B; Huber C; Kindler T; Fischer T
Leuk Res; 2008 Nov; 32(11):1698-708. PubMed ID: 18556063
[TBL] [Abstract][Full Text] [Related]
17. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
Kiyoi H; Shiotsu Y; Ozeki K; Yamaji S; Kosugi H; Umehara H; Shimizu M; Arai H; Ishii K; Akinaga S; Naoe T
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4575-82. PubMed ID: 17671144
[TBL] [Abstract][Full Text] [Related]
18. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
[TBL] [Abstract][Full Text] [Related]
19. Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.
Hong Z; Xiao M; Yang Y; Han Z; Cao Y; Li C; Wu Y; Gong Q; Zhou X; Xu D; Meng L; Ma D; Zhou J
Carcinogenesis; 2011 Oct; 32(10):1550-8. PubMed ID: 21803735
[TBL] [Abstract][Full Text] [Related]
20. [New therapeutic option for leukemia patients, with FLT3/Aurora kinase inhibitor, KW-2449: strategy and comparison with other kinase inhibitors].
Shiotsu Y
Rinsho Ketsueki; 2008 Aug; 49(8):641-9. PubMed ID: 18800614
[No Abstract] [Full Text] [Related]
[Next] [New Search]
